- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03224429
Sickle Cell Disease (SCD) Decision Aid
Comparative Effectiveness of a Decision Aid for Therapeutic Options in Sickle Cell Disease
The purpose of this study is to gather decision making needs information from caregivers and patients with sickle cell disease (SCD) in order to develop a web-based decision aid tool. Study subjects will participate in interviews defining treatment decision making needs during which investigators will ask information about their SCD. Notes taken from these interviews will allow the research team to better understand current practice related to clinical practice and allow for better refinement of the decision aid tool.
An additional group of participants will be asked to review the web-based Sickle Cell Decision Aid. Participants will be asked to describe thoughts about the site, including but not limited to ease of navigation, content and construction.
This study will provide information for the conduct of a randomized controlled trial for the use of a web based decision aid to give patients with sickle cell disease and parent/legal guardian of children with sickle cell disease accurate information about risks and benefits of therapies and enable them to make decisions based on their individual values and preferences.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The purpose of this study is to understand patient, family and caregiver needs when making a decision about treatment for their sickle cell disease (SCD). Investigators are developing a decision aid tool that can help people understand SCD treatment options.
One group of subjects will participate in qualitative interviews defining treatment decision making needs during which investigators will ask information about their SCD. Investigators will also discuss treatment choices: hydroxyurea, chronic or monthly blood transfusions and bone marrow transplantation. Participants will be asked their thoughts about how to develop a web-based decision aid tool. Notes taken from these interviews will allow the research team to better understand current practice related to clinical practice and allow for better refinement of the decision aid tool.
An additional group of subjects will review the web-based Sickle Cell Decision Aid. Participants will be asked to navigate the site. As the participant navigates the site, the study interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction. Testing may be performed in-person or via telephone. Using qualitative data collection methods, questions will be analyzed allowing for increased focus of questions based on common themes and issues identified during ongoing analysis.
This study will provide information for the conduct of a randomized controlled trial for the use of a web based decision aid to give patients with sickle cell disease and parent/legal guardian of children with sickle cell disease accurate information about risks and benefits of therapies and enable them to make decisions based on their individual values and preferences.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-Individual diagnosed with sickle cell disease (SCD) or parent/legal guardian/caregiver of individual (of any age) diagnosed with SCD
Exclusion Criteria:
There are no exclusions to study participation.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Decisional Needs Assessment
Caregivers and patients with sickle cell disease will participate in a semi-structured open ended interview regarding treatment decision making.
|
Subjects will participate in an open-ended interview regarding type of sickle cell disease, complications, current treatment, and experiences with decision making and sickle cell treatment.
Participants will be asked to describe what is important when making health care decisions.
Treatment options (hydroxyurea, chronic or monthly blood transfusions, and bone marrow transplantation) will be discussed as well as how a web-based decision aid tool should be developed.
The interview will be audio recorded and will take 45 to 60 minutes to complete.
|
|
Autre: Beta Testing
Caregivers and patients with sickle cell disease will review the web-based Sickle Cell Decision Aid.
|
Participants will be asked to navigate the Sickle Cell Decision Aid site that provides information about risks and benefits of therapies.
As the participant navigates the site, the interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction.
Testing may be performed in-person or via telephone.
Interviews will be audio recorded and take up to 60 to 90 minutes to complete.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Patient/Caregiver Knowledge of Treatment Risks
Délai: Up to 90 Minutes
|
Patient and caregiver knowledge of treatment risks will be collected via an open-ended semi- structured interview and aggregated as qualitative data to identify common knowledge gaps.
|
Up to 90 Minutes
|
|
Patient/Caregiver Knowledge of Treatment Benefits
Délai: Up to 90 Minutes
|
Patient and caregiver knowledge of treatment benefits will be collected via an open-ended semi- structured interview and aggregated as qualitative data to identify common knowledge gaps.
|
Up to 90 Minutes
|
|
Patient/Caregiver Treatment Expectations
Délai: Up to 90 Minutes
|
Patient and caregiver treatment expectations will be collected via an open-ended semi- structured interview and aggregated as qualitative data to identify common knowledge gaps.
|
Up to 90 Minutes
|
|
Barriers to Understanding Treatment Options
Délai: Up to 90 Minutes
|
Patient and caregiver knowledge of treatment options will be collected via an open-ended semi- structured interview and aggregated as qualitative data to identify common knowledge gaps.
|
Up to 90 Minutes
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IRB00076096
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Drépanocytose
-
Patrick C. Johnson, MDRecrutement
-
The Lymphoma Academic Research OrganisationBristol-Myers Squibb; Novartis; Gilead SciencesRecrutementÉligible en hématopathologie ou traitement CAR-t CellFrance
-
Stiftung Swiss Tumor InstituteKlinik Hirslanden, Zurich; Palleos Healthcare GmbHRecrutementMesures des résultats rapportés par les patients | Thérapie CAR T-CellSuisse
-
Dartmouth-Hitchcock Medical CenterComplétéLymphome | Leucémie | Myélome multiple | Greffe de cellules souches | Greffe de cellules souches hématopoïétiques | Thérapie CAR T-Cell | GCSH | Thérapie cellulaire | Transplantation CAR T-CellÉtats-Unis
-
University of California, San DiegoRecrutementThérapie CAR T-CellÉtats-Unis
-
University of Modena and Reggio EmiliaAzienda Unita Sanitaria Locale Reggio EmiliaPas encore de recrutementGreffe de cellules souches | Immunothérapie | Thérapie CAR T-CellItalie
-
Shenzhen Fifth People's HospitalRecrutement
-
University of ArizonaNational Cancer Institute (NCI)RecrutementLymphome | Leucémie | Thérapie cellulaire | Perfusion de lymphocytes de donneur | Transplantation de cellules souches hématopoïétiques | Thérapie CAR T-CellÉtats-Unis
-
Manchester University NHS Foundation TrustUniversity of Manchester; The Christie NHS Foundation Trust; Zenzium AI Ltd.; Aptus... et autres collaborateursRecrutementCancer colorectal | Cancer du poumon | Cancer hématologique | Thérapie CAR T-CellRoyaume-Uni
-
Sun Yat-sen UniversityComplétéCancer du col de l'utérus | Effet de la chimiothérapie | Thérapie néoadjuvante | Programmed Cell Death 1 Receptor / Antagonistes et inhibiteursChine